A phase II study of high-dose octreotide in patients with unresectable pancreatic carcinoma

European Journal of Cancer

Volumn 35, Issue 13, 1999, Pages 1805-1808

  Sulkowski, U ^a   Buchler M ^b   Pederzoli, P ^c   Arnold, R ^d   Dinse, P ^e   Kay, A ^f   Haus, U ^g   Beger, H G ^h  

^a Soest City Hospital   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c POLICLINICO BORGO ROMA   (Italy)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f NOVARTIS PHARMA AG   (Switzerland)

^g NOVARTIS PHARMA GMBH   (Germany)

^h UNIVERSITY OF ULM   (Germany)

Author keywords

Hormonal therapy; Octreotide; Pancreatic carcinoma; Survival

Indexed keywords

OCTREOTIDE;

ADULT; AGED; ARTICLE; BILIARY TRACT DISEASE; CANCER GROWTH; CANCER STAGING; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; INOPERABLE CANCER; LIVER DISEASE; MALE; METABOLIC DISORDER; NUTRITIONAL DISORDER; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PANCREATIC NEOPLASMS;

EID: 0344500650     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00177-X     Document Type: Article

References (20)

1. Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer 1987, 60, 2284-2303.
2. Ishikawa O. Surgical technique, curability and postoperative quality of life in an extended pancreatectomy for adenocarcinoma of the pancreas. Hepatogastmentemlogy 1996, 43, 320-325.
3. Prott FJ. Schönekaes K, Preusser P, et al. Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study. Br J Cancer 1997, 75, 597-601.
4. Sulkowski U. Standards and perspectives in the diagnosis and treatment of pancreatic adenocarcinoma. Digestion 1996, 57(Suppl. 1), 34-35.
5. Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer 1996, 78(Suppl.), 654-663.
6. Fennelly D, Kelsen DP. The role of chemotherapy in the treatment of adenocarcinoma of the pancreas. Hepatogastmenterology 1996,43,356-362.
7. Gelber RD. Gemcitabine for pancreatic cancer: How hard to look for clinical benefit? An American perspective. Ann Oncol 1996,7, 335-337.
8. Moore M. Activity of gemcitabine in patients with advanced pancreatic carcinoma. Cancer 1996, 78(Suppl. 3), 633-638.
9. Rosenberg L, Barkun AN, Denis MH, Pollak M. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 1995, 75, 23-28.
10. Ebert M, Friess H, Beger HG, Büchler MW. Role of octreotide in the treatment of pancreatic cancer. Digestion 1994, 55(Suppl. 1), 48-51.
11. Schally AV. Oncological applications of somatostatin analogs. Cancer Res 1988, 48, 6977-6985.
12. Klijn JGM, Hoff AM, Planting AST, et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 1990, 62, 627-630.
13. Muchmore JH, Carter RD, Preslan JE, George WJ. Regional chemotherapy with hemofiltration: a rationale for a different treatment approach to advanced pancreatic cancer. Hepatogastroenterology 1996, 43, 346-355.
14. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996, 7, 347-353.
15. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994, 12, 29-34.
16. Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. BrJ Cancer 1996, 73, 101-105.
17. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15, 2403-2413.
18. Cascinu S, Del Ferro E, Catalano G. A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer 1995,71,97-101.
19. Tan CK, Podila PV, Taylor JE, et al. Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology 1995, 108, 1908-1916.
20. Reubi JC, Waser B, Friess H, Buchler M, Laissue J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 1998, 42, 546-550.